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Transcription factor c-Myb promotes the invasion








Background: Specific gene expression is tightly regulated by various transcription factors. Osteopontin (OPN) is a
phosphoprotein that mediates hepatocellular carcinoma (HCC) progression and metastasis. However, the
mechanism of OPN up-regulation in HCC metastasis remains to be clarified.
Methods: Oligonucleotide array-based transcription factor assays were applied to compare different activities of
transcription factors in two human HCC cell lines with different OPN expression levels. The effects of one selected
transcription factor on OPN expression were further evaluated.
Results: Eleven transcription factors were over-expressed in metastatic HCC cell line HCCLM6 cells whereas twelve
transcription factors were down-regulated. Electrophoretic mobility shift assays (EMSA) and reporter gene assays
showed that one of up-regulated transcription factors c-Myb could bind the OPN promoter and increase its
transcription activity. In addition, small interfering RNA targeting c-Myb could inhibit OPN expression and
significantly decrease migration and invasion of HCCLM6 cells in vitro.
Conclusion: Our data first demonstrate that c-Myb has a functionally important role in the regulation of OPN
expression in HCC cells, suggesting that c-Myb might be a new target to control HCC metastasis.
1. Introduction
Hepatocellular carcinoma (HCC) is one of the most
common and aggressive malignancies [1]. Despite of
improvements in surgical techniques and perioperative
managements, HCC prognosis remains poor due to a
5-year recurrence rate of 50%-70% after resection [2,3].
Thus, it is critical to identify the molecules controlling
the invasive and metastatic potential of HCC, which
would provide new targets for intervention.
Osteopontin (OPN) is a secreted extracellular matrix
protein, which has been linked to tumor progression
and metastasis in a variety of cancers including HCC
[4,5]. OPN has been identified as the lead gene over-
expressed in the metastatic HCC [6]. Increased OPN
expression is associated with clinical stage, portending a
poor prognosis [7-9]. OPN increases cell proliferation,
migration and extracellular matrix invasion in vitro
through binding its receptors of integrins or CD44 variant.
Although OPN has been studied in a number of tumors,
the molecular mechanisms of OPN up-regulation in the
processes of HCC metastasis are still elusive.
While tumor progression and metastasis are closely
related to signaling cascades that transduce and inte-
grate regulatory cues, transcription factors are endpoints
of signaling pathways to determine transcription and the
extent to which genes are expressed [10]. In addition,
some transcription factors including AP-1 [11], SP-1
[12] and Runx [13] have been functionally associated
with tumor cell proliferation, growth, differentiation and
metastasis in leukemia and solid tumors.
To investigate the possibility that transcription factors
regulate OPN expression in HCC metastasis, we applied
transcription factor microarrays to compare different
activities of transcription factors in two human HCC
cell lines with different OPN expression levels. Our data
demonstrate that one of up-regulated transcription fac-
tors c-Myb plays an important role in the regulation of
OPN expression and invasion of HCC cells in vitro,
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trol HCC metastasis.
2. Materials and methods
2.1 Cell culture
Human embryonic liver cell line L02 and HCC cell line
SMMC-7721 were obtained from Shanghai Institute of
Cell and Biology, Chinese Academy of Science and
maintained in RPMI supplemented with 10% fetal
bovine serum at 37°C with 5% CO2. Human metastatic
HCC cell line MHCC97-L and HCCLM6 were estab-
lished at Liver Cancer Institute, Zhongshan Hospital,
Fudan University, Shanghai, P.R. China [14] and cul-
tured in DMEM (Invitrogen, Carlsbad, CA) containing
10% fetal bovine serum at 37°C with 5% CO2.
2.2 RNA isolation and reverse transcription-PCR
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen, Carlsbad, California) and reverse transcribed
into single-stranded cDNA. PCR was done on cDNA
using oligo(dT) priming and amplified with the primer
pairs for a 436-bp fragment of OPN(forward primer
5’-GGACTCCATTGACTCGAACG-3’ and reverse
primer 5’-TAATCTGGACTGCTTGTGGC-3’)a n da
366-bp fragment of Glyceraldehyde-3- phosphate dehy-
drogenase (GAPDH) (forward primer 5’-ATCCCATC
ACCATCT TCCAG-3’ and reverse primer 5’-GAGTCC
TTCCACGA TACC AA-3’). GAPDH was used as a con-
trol. Ten microliters of PCR product was analyzed on 2%
agarose gels.
2.3 RNA isolation and real-time quantitative RT-PCR
RNA was isolated from cells using the TRIzol and was
reverse transcribed into cDNA by oligo(dT) primer.
QuantiTect SYBR Green PCR kit (Qiagen, Valencia,
CA) and DNA Engine Opticon System (MJ Research,
Reno, NV) were used for real-time PCR. Data were ana-
lyzed with Opticon Monitor software version 1.02. The
thermal cycling conditions comprised an initial dena-
turation step at 95°C for 15 minutes and 45 cycles at
94°C for 15 seconds and 55°C or 57°C for 1 minute. The
primers for c-Myb, OPN and GAPDH were shown in
Table 1. GAPDH was used as a control and relative
expression of genes was determined by normalizing to
GAPDH according to the manufacturer’s instructions.
2.4 Nuclear extracts and biotin-streptavidin DNA pull-
down assay
Oligonucleotide containing biotin on the 5’-nucleotide
of the sense strand was used in the PCR amplification
for human OPN promoter. The sequences of the primer
were as follows: sense strand: 5’biotin-TGGAATAC
ATCCAATTTAAGGGAG-3’; antisense strand 5’-
GAATGCACAA CCCAGTAGCAAA-3’; which corre-
sponds to positions -1488 to +185 of the human OPN
promoter. Nuclear proteins were isolated from HCC cell
line SMMC-7721 and HCCLM6 cells respectively
according to manufacturer’s directions (NE-PER nuclear
and cytoplasmic extraction reagents, Pierce). Protein
concentration of the nuclear extract was determined
using a BCA assay kit. The nuclear protein was incu-
bated for 1 hour at 25°C with biotinylated PCR product
bound to streptavidin agarose beads in protein binding
buffer (12% (v/v) glycerol, 24 mM HEPEs PH 7.9, 8 mM
Tris PH 7.9, 300 mM KCl, 2 mM EDTANa2 0.25 mg/ml
poly(dI-dC)). The magnetic beads were washed three
times with protein binding buffer and the fractions were
eluted with elution buffer (2.0 M NaCl, 20 mM Tris-
HCL, pH 8.0, 10%(v/v) glycerol, 0.01%(v/v)Triton X-100,
1 . 0m ME D T A ,1m Md i t h i o t h r e i t o l )a n dw e r es t o r e d
at -80°C.
2.5 Transcription factor profiling
TranSignal Protein/DNA Microarray I (SuperArray,
Bethesda, MD) was used to characterize the transcrip-
tion factor profiles of SMMC-7721 and HCCLM6 cells.
The chip included 254 transcription factors. The nuclear
protein from DNA pull-down assay was incubated for
30 minute at 15°C with the TranSignal probes, and then
the compounds was washed three times with wash buf-
fer and eluted with elution buffer to get the probes.
When used, probes from three independent expreri-
ments were taken and mixed by equal volume. Then,
probes were hybridized with microarrays performed
according to the manufacturer’s instructions as
described previously [15].
Table 1 Primers of c-Myb and OPN for real-time quantitative RT-PCR
Gene Primer sequence (5’®3’) Annealing temperature(°C) Product length (bp)
c-Myb TACAATGCGTCGGAAGGTCG 55 201
GCGGAGCCTGAGCAAAACC
OPN GTGGGAAGGACAGTTATGAAACG 57 134
CTGACTATCAATCACATCGGAAT
GADPH ATGACCCCTTCATTGACC 55 131
GAAGATGGTGATGGGATTTC
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Nuclear extract preparation and electrophoretic mobility
shift assays were conducted as described previously [12].
The oligonucleotides containing c-Myb-binding site
were used in EMSA according to the manufacturer’s
instructions (Chemiluminescent nucleic acid detection
module, Pierce). The oligonucleotides were labeled with
biotin according to standard protocols. The sequences
of the oligonucleotides were as follows: 5’Biotin-
TAC AGGCATAACGGTTCCGTAGTGA-3’. The point
mutant (underlined) of oligonucleotides was con-
structed: 5’Biotin-TACAGGCATATCGGTTCCGTAG
TGA-3’. The oligonucleotides was annealed to its com-
plementary oligonucleotides and incubated with nuclear
proteins for 30 minute at 25°C. Samples were run on a
6% polyacrylamide gel, which was transfered into Nylon
member and then blocked and washed. Bands were
detected by chemiluminescent method.
2.7 Luciferase Assay
The OPN promoter was amplified by from HCCLM6
cells as described above [12]. The amplified OPN pro-
moter encompassed all c-Myb binding sites to test tran-
scriptional activity [16]. The resulting 1673-bp fragment
(-1488 to +185) was ligated into the Kpn I and Xhol I
sites of the pGL3-Basic luciferase reporter vector (Pro-
m e g a ,M a d i s o n ,W I ) .I nb r i e f ,4x 1 0
5 cells were seeded
the day before transfection. Then, 2 ug of plasmid DNA
and 4 ul of LipofectAMINE 2000 (Invitrogen, Carlsbad,
CA), diluted with Opti-MEM, were mixed gently and
incubated with cells. Together, the small RNA interfer-
ence (siRNA) targeting c-Myb was chemically synthe-
sized and tranfected into cells using LipofectAMINE
2000. Culture medium was changed after 6 hours of
transfection. Cells were washed with PBS and lysed in
lysis buffer after 36 hours after transfection according to
the manufacturer’s instructions. Luciferase activity was
measured by luminometer (Lumat LB970). Luciferase
activity was normalized for b-Galactosidase (pSV-b-
Galactosidase Control Vector). Experiments were per-
formed in triplicate.
2.8 Small Interfering RNA (siRNA)
The Sequence targeted to the site of c-Myb mRNA (Gen-
eBank Accession No. NM_005375) were designed with-
out off-target effects. The sense and antisense strands of
c-Myb siRNAs were 5’-GGACGAACUGAUAAUG-
CUATT-3’ and 5’-UAGCAUUAU CAGUUCGUCCAG-
3’, respectively. For transfection of the HCC cells, c-Myb
siRNA or a negative-control mismatch sequence (scram-
ble siRNA) was transfected with LipofectAmine 2000
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions.
2.9 Western blot
Total protein extraction from cultured cells was used in
electrophoresis and western blot. Briefly, twenty micro-
grams of total protein were separated by standard SDS-
PAGE and then transferred to PVDF membranes. The
membranes were washed, blocked, and incubated with
the specific primary antihuman antibodies against OPN
(1:800) or against c-Myb (1:500), anti-GADPH antibody
(1:5000) (Santa Cruz), followed by incubation with
horseradish peroxidase-conjugated secondary antibodies.
The reactions were detected by enhanced chemilumines-
cence assay.
2.10 Matrigel invasion assay and migration assay
The invasive ability of the transfected cells was deter-
mined by the Matrigel (BD Pharmingen) coated 24-well
transwell chambers with upper and lower culture com-
partments separated by polycarbonate membranes with
8-um pore(Costar, NY, USA). The bottom chamber was
filled with DMEM containing 10% FBS as a chemoat-
tractant. The transfected cells (1 × 10
5) were seeded on
the top chamber and incubated at 37°C with 5% CO2.
After 40 hours, the cells removed from the upper sur-
face of the Matrigel by scrubbing with a cotton swab
and cells that migrated to the underside of the mem-
brane were stained with Giemsa (Sigma). Five high-
power fields were counted and the mean number of
cells per field was calculated. The migration assay was
similar to the invasion assay only without Matrigel and
lasted for 18 hours. The experiments were performed in
triplicate.
2.11 Statistical analysis
Statistical analyses were performed by the Statistical
Package for the Social Sciences version 11.5 (SPSS, Inc.,
Chicago, IL). Data were expressed as means ± SD, and
analyzed using the two-tailed Student’st - t e s to rt h e
Analysis of Variance (ANOVA). The level of significance
was set at P < 0.05.
3. Results
3.1 Differential activity of transcription factors in two HCC
cell lines with different OPN expression levels
Compared to the weakly tumorigenic and non-metastastic
HCC cell line SMMC-7721 cells, HCCLM6 cells with
highly metastatic potential expressed high level of OPN
(Figure 1A, C). With > 2-fold or < 0.5-fold expression as
the cutoff point, analysis of transcription factor profiles
revealed that eleven transcription factors including c-Myb,
MAZ and E4BP4 were highly up-regulated meanwhile
twelve transcription factors were reduced in HCCLM6
cells (Table 2). In particular, the expression of c-Myb was
at a high level in metastatic HCC cell line HCCLM6 and
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Page 3 of 8Figure 1 Verification of difference of OPN and c-Myb expression in HCC cell lines. HCCLM6 cells expressed high level of OPN and c-Myb
compared with SMMC-7721 cells. (A) Relative OPN and c-Myb mRNA levels in different cell lines by RT-PCR analysis. (B) Real-time quantitative
PCR analysis confirmed the difference of c-Myb mRNA expression in different cell lines. Graph depicted relative expression of OPN mRNA
normalized to that of GAPDH. The mRNA expression of c-Myb in HCCLM6 was used as control. Data expressed as means ± SD (*P < 0.05,
SMMC-7721 vs. HCCLM6). (C)Western blot analysis of OPN and c-Myb protein expression in HCC cell line SMMC-7721 and HCCLM6. Blot was
representative of three experiments.
Table 2 Differential activity of transcription factorsin two HCC cell lines (SMMC-7721, HCCLM6) with different OPN
expression levels (> 2 fold or <0.5-fold change)
Name HCCLM6/SMMC-7721 ratio Description
Up-regulation
MAZ 3.10 MYC-associated zinc finger protein
E4BP4 2.86 nuclear factor, IL- 3 regulated
c-Myb 2.80 v-myb myeloblastosis viral oncogene
GATA-2 2.74 GATA binding protein 2
TEF1 2.73 activator
PEBP2 2.39 polyoma enhancer binding protein 2
Smad3/4 2.27 MADH3/4
IRF-1/2 2.21 interferon regulatory factor 1/2
PEBP 2.13 polyoma enhancer binding protein
GAG 2.13 amyloid precursor protin (APP) regulator
ADR1 2.10 alcohol dehydrogenase regulatory gene 1
Down-regulation
NF-E2 0.19 nuclear factor (erythroid-derived 2), 45 kDa
EGR 0.21 early growth response
C/EBPa 0.22 CCAAT/enhancer binding protein alpha
E2F-1 0.28 E2F transcription factor 1
CYP1A1 0.30 cytochrome P450-c
HiNF-A 0.31 A nuclear protein
Sp1 0.31 Sp1 transcription factor
E12/E47 0.31 enhancer binding factors E12/E47
PARP 0.34 poly(ADP-ribose) synthetase/polymerase
ELK1 0.34 member of ETS oncogene family
E4F1 0.34 E4F transcription factor 1
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SMMC-7721 cells, and barely detectable in normal cell
line L02 cells. Corresponding to different OPN expres-
sion level (HCCLM6 > MHCC-97-L> SMMC-7721),
the expression level of c-Myb increased sharply in
HCCLM6 cells (Figure 1A). Similar results were
obtained in real-time PCR analysis. When normalized
to the internal standard control, mRNA expression of
c-Myb in HCCLM6 cells was significantly higher than
SMMC-7721 cells (Figure 1B). Similar to the result of
mRNA expression, the difference of c-Myb protein
expression between HCCLM6 and SMMC-7721 cells
was also significant. (Figure 1C)
3.2 Transcription factor c-Myb contributing to
transcription activation of the OPN promoter in HCCLM6
cells
Having shown that c-Myb was over-expressed in HCCLM6
cells, we next sought to establish whether it has a function-
ally important role in the regulation of OPN expression.
To establish if functional c-Myb is present in HCCLM6
cells, nuclear extracts were incubated with the oligonucleo-
tides containing c-Myb-binding site and the formation of
specific complexes was determined by EMSA. A double-
stranded biotin-labeled oligonucleotides encompassing
the c-Myb site or a mutant form of the c-Myb site in the
OPN promoter were used. When nuclear extracts from
HCCLM6 cells was incubated with the oligonucleotides
containing c-Myb site, a specific retarded complex was
observed. In contrast, incubation with the oligonucleotides
containing mutant c-Myb site significantly abrogated bind-
ing (Figure 2A). In addition, the oligonucleotides contain-
ing the c-Myb site incubated with nuclear extracts from
SMMC-7721 cells formed a weakly specific retarded com-
plex (Figure 2A). These data demonstrate that the c-Myb
site in the OPN promoter can be specifically bound by
transcription factor c-Myb in HCCLM6 cells.
To further determine whether the c-Myb site in the OPN
promoter was required for transcription activation,
HCCLM6 cells were transfected with an OPN promoter
reporter plasmid. To assess whether down-regulation of
c-Myb could suppress the transcription activity of the
OPN promoter, HCCLM6 cells were co-transfected with
the OPN promoter reporter and siRNA targeting c-Myb.
Inhibition of c-Myb expression by siRNA significantly
decreased OPN promoter activity in HCCLM6 cells. In
contrast, co-transfection of the OPN promoter reporter
and a scramble siRNA had no effect on the activity of the
OPN promoter (Figure 2B). These data demonstrate that
c-Myb is essential for transcription activity of OPN in
HCCLM6 cells.
3.3 OPN expression was down-regulated after c-Myb was
inhibited in HCCLM6 cells
To further validate c-Myb regulating OPN expression in
HCCLM6 cells, we examined the level of OPN expression
Figure 2 Electrophoretic mobility shift sssays (EMSA) of c-Myb binding to OPN promoter and transient transfection analysis of OPN
promoter activity. (A). EMSA were performed using nuclear extract prepared from SMMC-7721 and HCCLM6 cells. Assays utilized a labeled
probe of 25-nt fragment containing the area of c-Myb binding site in the OPN promoter or a mutant form of the c-Myb binding site (c-Myb-
binding site TAACGG was mutated to TATCGG). The blot was representative of three experiments. (B) To confirm the role of c-Myb in the
increased OPN protein expression in HCCLM6 cells, Human OPN promoter (-1488 to +185 nt) was cloned into the pGL3-basic luciferase reporter
vector. The OPN promoter reporter constructs were transfected into HCCLM6 cells. In certain instances, c-Myb siRNA or scramble siRNA was co-
transfected. Luciferase activity was normalized to that of b-galactosidase activity. Data are presented as means ± SD of three experiments.
(*P < 0.05, c-Mb siRNA-treated group vs. scramble siRNA group).
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c-Myb. The results showed that inhibition of c-Myb
expression by siRNA significantly decreased OPN mRNA
and protein expression (Figure 3A, B), suggesting that
c-Myb contributes to the regulation of OPN expression
in HCCLM6 cells.
3.4 Migration and invasion of HCCLM6 cells in vitro were
inhibited by c-Myb siRNA
As migratory and invasive behaviors are the indicators
of the metastatic potential, we examined migration and
invasion of HCCLM6 cells in vitro using the transwell
assay after c-Myb expression was inhibited by c-Myb
siRNA. The average numbers of HCCLM6 cells trans-
fected with c-Myb siRNA migrating toward the condi-
tioned medium or invading through the Matrigel were
significantly fewer than those transfected with scramble
siRNA (Migration assay: 17.60 ± 4.04 vs 33.60 ± 4.67, P
< 0.05; Invasion assay: 8.00 ± 2.55 vs 18.8 ± 4.15,
P < 0.05, Figure 4), This result showed that the capabil-
ity of migration and invasion in HCCLM6 cells was sig-
nificantly decreased after inhibition of c-Myb, suggesting
that c-Myb is an important contributor to the migration
and invasion of HCC cells.
Discussion
Metastasis remains one of the major challenges for HCC
patients undergoing various therapies including liver
resection, local ablation and chemoembolization [2,3].
Previous work at our institute has shown that OPN gene
is over-expressed in the metastatic HCC [6]. In this
study, we searched for transcription factors that were
correlated with OPN expression in HCC cells and
revealed that transcription factor c-Myb was positively
associated with OPN expression in HCC cells, which can
bind the OPN promoter and increase its transcription
activity. Inhibition of c-Myb by siRNA decreased the
transcription activity of the OPN promoter, reduced the
expression of OPN, and compromised the ability for
migration and invasion of HCC cells. Therefore, our
results demonstrate that c-Myb plays an important role
in regulating OPN expression in HCC cells, suggesting
c-Myb might be a novel target for therapeutic intervention.
OPN is known to mediate correlates of metastatic
biology in a variety of cancers including HCC. Thus,
modulating OPN expression might be a novel approach
of suppressing tumor metastasis [17-19]. Transcription
factors are located at endpoints of signaling pathways
and integrate various stimuli to determine which genes
are expressed or suppressed [10]. To search for the
determinant transcription factors regulating OPN in
HCC, we used transcription factor microassays to com-
pare differential activities of transcription factors
between two HCC lines with different OPN expression
Figure 3 The effect of c-Myb on OPN expression of HCCLM6 cells. (A) OPN mRNA expression in HCCLM6 cells transfected with c-Myb siRNA
was significantly decreased. (*P < 0.05, vs control). The mRNA expression of OPN in cells transfect with scramble siRNA was used as control.
(B) OPN protein expression in HCCLM6 cells transfected with c-Myb siRNA was significantly reduced compared with cells transfected with
sramble siRNA. Blot was representative of three experiments.
Figure 4 Migration and invasion of HCCLM6 cells in response
to transfection of c-Myb siRNA. The c-Myb siRNA could
significantly inhibit the migration and invasion of HCCLM6 cells
compared with cells treated with scramble siRNA (*P < 0.05). The
migration and invasion assays were assessed by transwell chambers.
Data were expressed as means ± SD of three experiments.
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transcription factors were highly expressed meanwhile
twelve were down-regulated in metastatic HCC cells.
Transcription factor c-Myb was selected for further
investigation. The reasons are the following: (1) after
predicting the potential transcription factors in the OPN
promoter in the TRANSFAC database http://www.gene-
regulation.com and searching the reported transcription
factor which can bind to the OPN promoter in the
literature [20], we have found that among the eleven
up-regulated transcription factors, c-Myb and IRF-1
have the definitive binding sites in the OPN promoter.
Although the rests of transcription factors were up-
regulated in gene-chip analysis, they lacked the reported
binding site in the OPN promoter and may act by the
way of combining with co-activators or other transcrip-
tion factors, and then together binding to specific sites
of the OPN promoter. (2) Interestingly, Schultz J and
colleagues [21] have reported that differential capability
of c-Myb binding to -443T/C osteopontin promoter
influences osteopontin gene expression in melanoma
cells, suggesting the importance of c-Myb regulating
OPN expression in tumor progression. In this study,
c-Myb expression increased corresponding to OPN
levels in different HCC cell lines, suggesting that c-Myb
is associated with OPN expression. The differences of
OPN expression might reflect the differential activities
of c-Myb among HCC cell lines. EMAS and luciferase
assays further demonstrated that c-Myb is essential for
transcription activity of OPN in HCC cells.
The transcription factor c-Myb has a key role in regu-
lating the exquisite balance among cell division, differ-
entiation and survival and has now been identified as an
oncogene involved in some human leukemia and solid
cancers [22-24]. Recently, it is reported that oncogene
c-Myb participates in the process of hepatitis B virus-
induced liver carcinogenesis [21]. When inappropriately
expressed, c-Myb appears to activate important gene
targets to promote cancer progression and metastasis.
These genes include cyclooxygenase-2 (COX-2) [25],
Bcl-2, BclX(L) [26] and c-Myc [27], which influence
diverse processes such as angiogenesis, proliferation and
apoptosis. As for HCC, Yang et al [28] has documented
that increased expression of c-Myb and Sp1 binding to
the methionine adenosyltransferase 2A (MAT2A) pro-
moter contribute to the up-regulation of MAT2A
expression. MAT2A can catalyze the formation of S-
adenosylmethionine to facilitate HCC growth. In the
present study, we first demonstrate that c-Myb is a new
transcription factor of regulating OPN expression in
HCC cells, providing at least one mechanism for up-
regulation of OPN expression in HCC invasion and
metastasis.
Considering transcription factors including AP-1, Sp-
1, v-Src, Runx and Tcf-4 participating in the transcrip-
tion regulation of OPN in other types of cancers [20,29],
and transcription factor along with co-activators or co-
repressors strategically binding to specific sites of target
gene promoters [30], it is possible that c-Myb interacts
with other transcription factors to modulate the
OPN expression in HCC cells. This requires further
validation.
Apart from demonstrating the function of c-Myb in
the regulating OPN expression in HCC cells, we also
showed that down-regulation of c-Myb by siRNA
decreased OPN expression and also inhibited the migra-
tion and invasion of HCCLM6 cell in vitro, indicating
that modulating OPN expression by targeting c-Myb
might be a new approach for intervening HCC invasion
and metastasis. Antisense oligodeoxynucleotides target-
ing c-Myb, a dominant negative c-Myb or c-Myb
vaccine has shown an effective approach for therapy of
c-Myb dependent haematopoietic and epithelial malig-
nancies [31-33].
In summary, our data demonstrate that transcription
factor c-Myb is over-expressed in the metastatic HCC
cells and has a functionally important role in the regula-
tion of OPN expression, suggesting that c-Myb might be
a new target for therapeutic intervention in the HCC
invasion and metastasis by modulating OPN expression.
Acknowledgements
This work was sponsored by grants from China State Key Basic Research
Program Grant (No. 2004CB518708), National Natural Science Foundation of
China (No. 81000909), and Shanghai Natural Science Foundation
(09ZR1406400).
Author details
1Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai,
China.
2Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan
University), the Chinese Ministry of Education, Shanghai, 200032, China.
Authors’ contributions
CRX and SLY designed the study. CRX, YHX and TCX performed experiments.
CRX drafted the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 November 2010 Accepted: 30 December 2010
Published: 30 December 2010
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55:74-108.
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003,
362:1907-1917.
3. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y,
et al: A decade’s studies on metastasis of hepatocellular carcinoma. J
Cancer Res Clin Oncol 2004, 130:187-196.
4. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF,
Yeatman TJ: Correlation of osteopontin protein expression and
Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:172
http://www.jeccr.com/content/29/1/172
Page 7 of 8pathological stage across a wide variety of tumor histologies. Clin Cancer
Res 2004, 10:184-190.
5. Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling
and cancer progression. Trends Cell Biol 2006, 16:79-87.
6. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI,
Chen Y, et al: Predicting hepatitis B virus-positive metastatic
hepatocellular carcinomas using gene expression profiling and
supervised machine learning. Nat Med 2003, 9:416-423.
7. Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T,
Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G: Osteopontin
expression and prognostic significance in non-small cell lung cancer.
Clin Cancer Res 2005, 11:6459-6465.
8. Macri A, Versaci A, Lupo G, Trimarchi G, Tomasello C, Loddo S, Sfuncia G,
Caminiti R, Teti D, Famulari C: Role of osteopontin in breast cancer
patients. Tumori 2009, 95:48-52.
9. Yeatman TJ, Chambers AF: Osteopontin and colon cancer progression.
Clin Exp Metastasis 2003, 20:85-90.
10. Stein GS, Stein JL, Van Wijnen AJ, Lian JB, Montecino M, Croce CM, Choi JY,
Ali SA, Pande S, Hassan MQ, et al: Transcription factor-mediated
epigenetic regulation of cell growth and phenotype for biological
control and cancer. Adv Enzyme Regul 50:160-167.
11. Kajanne R, Miettinen P, Tenhunen M, Leppa S: Transcription factor AP-1
promotes growth and radioresistance in prostate cancer cells. Int J Oncol
2009, 35:1175-1182.
12. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X: Sp-1 and c-Myc
mediate lysophosphatidic acid-induced expression of vascular
endothelial growth factor in ovarian cancer cells via a hypoxia-inducible
factor-1-independent mechanism. Clin Cancer Res 2009, 15:492-501.
13. Blyth K, Cameron ER, Neil JC: The RUNX genes: gain or loss of function in
cancer. Nat Rev Cancer 2005, 5:376-387.
14. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY: Stepwise
metastatic human hepatocellular carcinoma cell model system with
multiple metastatic potentials established through consecutive in vivo
selection and studies on metastatic characteristics. J Cancer Res Clin
Oncol 2004, 130:460-468.
15. Deregibus MC, Cantaluppi V, Doublier S, Brizzi MF, Deambrosis I, Albini A,
Camussi G: HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-
dependent survival pathways in Kaposi’s sarcoma cells. J Biol Chem 2002,
277:25195-25202.
16. Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, Yamamoto S:
Cloning and characterization of the human osteopontin gene and its
promoter. Biochem J 1994, 303(Pt 1):255-262.
17. Shevde LA, Das S, Clark DW, Samant RS: Osteopontin: An Effector and an
Effect of Tumor Metastasis. Curr Mol Med 2010, 10(1):71-81.
18. Johnston NI, Gunasekharan VK, Ravindranath A, O’Connell C, Johnston PG,
El-Tanani MK: Osteopontin as a target for cancer therapy. Front Biosci
2008, 13:4361-4372.
19. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC: Osteopontin: an
emerging therapeutic target for anticancer therapy. Expert Opin Ther
Targets 2007, 11:81-90.
20. Wai PY, Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer
Metastasis Rev 2008, 27:103-118.
21. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M: The functional
-443T/C osteopontin promoter polymorphism influences osteopontin
gene expression in melanoma cells via binding of c-Myb transcription
factor. Mol Carcinog 2009, 48:14-23.
22. Ramsay RG, Gonda TJ: MYB function in normal and cancer cells. Nat Rev
Cancer 2008, 8:523-534.
23. Ramsay RG: c-Myb a stem-progenitor cell regulator in multiple tissue
compartments. Growth Factors 2005, 23:253-261.
24. Fang F, Rycyzyn MA, Clevenger CV: Role of c-Myb during prolactin-
induced signal transducer and activator of transcription 5a signaling in
breast cancer cells. Endocrinology 2009, 150:1597-1606.
25. Ramsay RG, Friend A, Vizantios Y, Freeman R, Sicurella C, Hammett F,
Armes J, Venter D: Cyclooxygenase-2, a colorectal cancer nonsteroidal
anti-inflammatory drug target, is regulated by c-MYB. Cancer Res 2000,
60:1805-1809.
26. Biroccio A, Benassi B, D’Agnano I, D’Angelo C, Buglioni S, Mottolese M,
Ricciotti A, Citro G, Cosimelli M, Ramsay RG, et al: c-Myb and Bcl-x
overexpression predicts poor prognosis in colorectal cancer: clinical and
experimental findings. Am J Pathol 2001, 158:1289-1299.
27. Greco C, Alvino S, Buglioni S, Assisi D, Lapenta R, Grassi A, Stigliano V,
Mottolese M, Casale V: Activation of c-MYC and c-MYB proto-oncogenes
is associated with decreased apoptosis in tumor colon progression.
Anticancer Res 2001, 21:3185-3192.
28. Yang H, Huang ZZ, Wang J, Lu SC: The role of c-Myb and Sp1 in the up-
regulation of methionine adenosyltransferase 2A gene expression in
human hepatocellular carcinoma. FASEB J 2001, 15:1507-1516.
29. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC:
The multifaceted roles of osteopontin in cell signaling, tumor
progression and angiogenesis. Curr Mol Med 2006, 6:819-830.
30. Ali SA, Zaidi SK, Dacwag CS, Salma N, Young DW, Shakoori AR,
Montecino MA, Lian JB, van Wijnen AJ, Imbalzano AN, et al: Phenotypic
transcription factors epigenetically mediate cell growth control. Proc Natl
Acad Sci USA 2008, 105:6632-6637.
31. Abaza MS, Al-Attiyah RJ, Al-Saffar AM, Al-Sawan SM, Moussa NM: Antisense
oligodeoxynucleotide directed against c-myb has anticancer activity and
potentiates the antiproliferative effect of conventional anticancer drugs
acting by different mechanisms in human colorectal cancer cells.
Tumour Biol 2003, 24:241-257.
32. Ramsay RG, Barton AL, Gonda TJ: Targeting c-Myb expression in human
disease. Expert Opin Ther Targets 2003, 7:235-248.
33. Funato T, Satou J, Kozawa K, Fujimaki S, Miura T, Kaku M: Use of c-myb
antisense oligonucleotides to increase the sensitivity of human colon
cancer cells to cisplatin. Oncol Rep 2001, 8:807-810.
doi:10.1186/1756-9966-29-172
Cite this article as: Chen et al.: Transcription factor c-Myb promotes the
invasion of hepatocellular carcinoma cells via increasing osteopontin
expression. Journal of Experimental & Clinical Cancer Research 2010 29:172.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:172
http://www.jeccr.com/content/29/1/172
Page 8 of 8